Muscadine Grapes

[JPM912]

Anyone has experience with muscadine grape skin capsules for prostate cancer.

[Kaliber]

I’ve got a lot of vines in my mini backyard vineyard… these are two species of muscadine. I’ve eaten them seasonally for over 20 years. Tasty but doesn’t seem like they had any impact on my getting PCa ….. dunno.

Vineyard grapes

[JPM912 in reply to Kaliber]

I found a study that the skin is the best to inhibit growth. Dosage might need to be higher. Google MKSE

[Kaliber in reply to JPM912]

I’ll check them out …thanks.

[JPM912 in reply to Kaliber]

Hope

Muscadine study

[Fightinghard in reply to Kaliber]

Hey Kaliber

For maximum effect, you should mash then ferment the grapes. Might not help PCA but should make you feel better right away

[Kaliber in reply to Fightinghard]

… I tried that early on, everything I made tasted awful. Now I make raisins instead , they taste great ….yayahahahaya yayahahahaya.

😂😂😂😂

Where I live in The Central Valley of California, we have about a million acres of wine grapes in production. Wine is really big business out here.

[Graham49]

Phase 1 trial not specific to PCa but it's a start.

"Higher MGE dose was correlated with improvement in self-reported physical well-being QOL at 8 weeks (r=0.6; P=0.04)."

"MGE is safe and well-tolerated in heavily pretreated and older cancer patients. The potential anticancer properties and the effects of MGE on physical well-being and QOL metrics will be evaluated in future studies."

Phase I Study of Muscadine Grape Extract for Patients With Advanced CancerBitting, Rhonda L. MD*,†; Tooze, Janet A. PhD*,‡; Isom, Scott MS*,‡; Petty, W. Jeffrey MD*,†; Grant, Stefan C. MD*,†; Desnoyers, Rodwige J. MD*,†; Thomas, Alexandra MD*,†; Thomas, Christopher Y. MD*,†; Alistar, Angela T. MD*,†; Golden, Shannon L. MA§; Pleasant, Katherine BA§; Chappell, Mark C. PhD§; Tallant, E. Ann PhD*,§; Gallagher, Patricia E. PhD*,§; Klepin, Heidi D. MD*,†Author Information

American Journal of Clinical Oncology: June 2021 - Volume 44 - Issue 6 - p 239-246

doi: 10.1097/COC.0000000000000814

Abstract

Objective:

Preclinical studies with muscadine grape extract (MGE) show antitumor activity and decreased systemic inflammation. This phase I study (NCT02583269) assessed safety and tolerability of a proprietary MGE preparation in patients with advanced solid tumors.

Methods:

Patients with metastatic or unresectable cancers who were progressing on standard therapies were assigned to MGE in a standard 3+3 design. Five dose levels were tested (320 to 1600 mg total phenolics/d). Safety and maximum-tolerated dose were assessed after 4 weeks. Patients were evaluated for response at 8 weeks and continued on MGE if clinically stable. Secondary outcomes were response, survival, adherence, fatigue, and quality of life (QOL).

Results:

In total, 23 patients (lung, n=7; gastrointestinal, n=7; genitourinary, n=6; other, n=3) received MGE capsules by mouth twice daily. The cohort [median age 72 years, 48% Eastern Cooperative Oncology Group (ECOG) 2] was heavily pretreated. After 4 weeks on MGE, possibly attributable adverse events grade 2 or higher were fatigue (n=1), decreased lymphocyte count (n=1), and constipation (n=2), including 1 dose-limiting toxicity for grade 3 constipation. Maximum-tolerated dose was not reached. No partial responses were observed. Median time on therapy was 8 weeks, with 29% of patients treated beyond 16 weeks and a median overall survival of 7.2 months. QOL and fatigue levels were stable from baseline to 8 weeks. Higher MGE dose was correlated with improvement in self-reported physical well-being QOL at 8 weeks (r=0.6; P=0.04).

Conclusions:

MGE is safe and well-tolerated in heavily pretreated and older cancer patients. The potential anticancer properties and the effects of MGE on physical well-being and QOL metrics will be evaluated in future studies.

[JPM912 in reply to Graham49]

MGE is different than MKSE no, skin versus seed